| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $12,611,360 | 11 | 100 |
| ten Bosch John Roderick | SVP of Laboratory Operations | 0 | $0 | 3 | $618,875 | $-618,875 |
| Tsao David | Chief Technology Officer | 0 | $0 | 2 | $2.58M | $-2.58M |
| Lynch Thomas P. | See Remarks | 0 | $0 | 1 | $3.87M | $-3.87M |
| Atay Oguzhan | Chairman and CEO | 0 | $0 | 5 | $5.54M | $-5.54M |
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal …
Over the last 12 months, insiders at BillionToOne, Inc. have bought $0 and sold $12.61M worth of BillionToOne, Inc. stock.
On average, over the past 5 years, insiders at BillionToOne, Inc. have bought $0 and sold $12.61M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-28 | Sale | Atay Oguzhan | Chairman and CEO | 11,000 0.0241% | $118.00 | $1.3M | -1.86% | |
| 2026-10-15 | Sale | Atay Oguzhan | Chairman and CEO | 5,150 0.0106% | $100.23 | $516,189 | +7.48% | |
| 2026-10-14 | Sale | Atay Oguzhan | Chairman and CEO | 5,850 0.0124% | $98.19 | $574,386 | +11.45% | |
| 2026-10-12 | Sale | Atay Oguzhan | Chairman and CEO | 19,334 0.0422% | $94.31 | $1.82M | +14.67% | |
| 2026-10-05 | Sale | ten Bosch John Roderick | SVP of Laboratory Operations | 2,834 0.0059% | $105.15 | $297,995 | -5.10% | |
| 2026-10-05 | Sale | Tsao David | Chief Technology Officer | 20,000 0.0427% | $108.15 | $2.16M | -5.10% | |
| 2026-09-28 | Sale | Atay Oguzhan | Chairman and CEO | 10,999 0.0235% | $120.64 | $1.33M | -13.14% | |
| 2026-09-24 | Sale | ten Bosch John Roderick | SVP of Laboratory Operations | 1,416 0.0029% | $120.00 | $169,920 | -15.27% | |
| 2026-09-24 | Sale | Tsao David | Chief Technology Officer | 3,333 0.0072% | $125.00 | $416,625 | -15.27% | |
| 2026-09-21 | Sale | ten Bosch John Roderick | SVP of Laboratory Operations | 1,416 0.0031% | $106.61 | $150,960 | +2.48% | |
| 2026-09-17 | Sale | Lynch Thomas P. | See Remarks | 35,112 0.0761% | $110.33 | $3.87M | -4.29% |
| Increased Positions | 88 | 0% | 9M | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 88 | New | 9M | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 88 | 0% | 9M | 0% |